Literature DB >> 9234799

A role for PACE4 in the proteolytic activation of anthrax toxin protective antigen.

V M Gordon1, A Rehemtulla, S H Leppla.   

Abstract

Several bacterial protein toxins require activation by eukaryotic proteases. Previous studies have shown that anthrax toxin protective antigen (PA), Pseudomonas exotoxin A (PE), and diphtheria toxin (DT) are cleaved by furin C-terminal to the sequences RKKR, RQPR, and RVRR, respectively. Because furin-deficient cells retain some sensitivity to PA and DT, it is evident that other cellular proteases can activate these toxins. Whereas furin has been shown to require arginine residues at positions -1 and -4 for substrate recognition, another protease with an activity which could substitute for furin in toxin activation, the furin-related protease PACE4, requires basic residues in the -1, -2, and -4 positions of the substrate sequence. To examine the relative roles of furin and PACE4 in toxin activation, we used furin-deficient CHO cells (FD11 cells) transfected with either the furin (FD11/furin cells) or PACE4 (FD11/PACE4 cells) gene. Mutant PA proteins containing the cleavage sequence RAAR or KR were cytotoxic toward cells expressing only PACE4. In vitro cleavage data demonstrated that PACE4 can recognize RAAR and, to a much lesser extent, KR and RR. When extracts from PACE4-transfected cells were used as a source of proteases, PACE4 had minimal activity, indicating that it had been partially inactivated or did not remain associated with the cell membranes. Cleavage of iodinated PA containing the sequence RKKR or RAAR was detected on the surface of all cell types tested, but cleavage of a dibasic sequence was detected only intracellularly and only in cells that expressed furin or PACE4. The data provide evidence that PACE4 is present at the exterior of cells, that it plays a role in the proteolytic activation of anthrax toxin PA, and that PACE4 can activate substrates at the sequence RAAR or KR.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9234799      PMCID: PMC175476          DOI: 10.1128/iai.65.8.3370-3375.1997

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  25 in total

Review 1.  Mammalian subtilisins: the long-sought dibasic processing endoproteases.

Authors:  P J Barr
Journal:  Cell       Date:  1991-07-12       Impact factor: 41.582

2.  Identification of a second human subtilisin-like protease gene in the fes/fps region of chromosome 15.

Authors:  M C Kiefer; J E Tucker; R Joh; K E Landsberg; D Saltman; P J Barr
Journal:  DNA Cell Biol       Date:  1991-12       Impact factor: 3.311

3.  Preferred sequence requirements for cleavage of pro-von Willebrand factor by propeptide-processing enzymes.

Authors:  A Rehemtulla; R J Kaufman
Journal:  Blood       Date:  1992-05-01       Impact factor: 22.113

4.  Production and purification of anthrax toxin.

Authors:  S H Leppla
Journal:  Methods Enzymol       Date:  1988       Impact factor: 1.600

Review 5.  Proteolytic activation of bacterial toxins: role of bacterial and host cell proteases.

Authors:  V M Gordon; S H Leppla
Journal:  Infect Immun       Date:  1994-02       Impact factor: 3.441

6.  Expression cloning of a diphtheria toxin receptor: identity with a heparin-binding EGF-like growth factor precursor.

Authors:  J G Naglich; J E Metherall; D W Russell; L Eidels
Journal:  Cell       Date:  1992-06-12       Impact factor: 41.582

7.  Functional mapping of anthrax toxin lethal factor by in-frame insertion mutagenesis.

Authors:  C P Quinn; Y Singh; K R Klimpel; S H Leppla
Journal:  J Biol Chem       Date:  1991-10-25       Impact factor: 5.157

8.  Anthrax toxin protective antigen is activated by a cell surface protease with the sequence specificity and catalytic properties of furin.

Authors:  K R Klimpel; S S Molloy; G Thomas; S H Leppla
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-01       Impact factor: 11.205

9.  Characterization of a cellular protease that cleaves Pseudomonas exotoxin.

Authors:  C Fryling; M Ogata; D FitzGerald
Journal:  Infect Immun       Date:  1992-02       Impact factor: 3.609

10.  Fusions of anthrax toxin lethal factor to the ADP-ribosylation domain of Pseudomonas exotoxin A are potent cytotoxins which are translocated to the cytosol of mammalian cells.

Authors:  N Arora; K R Klimpel; Y Singh; S H Leppla
Journal:  J Biol Chem       Date:  1992-08-05       Impact factor: 5.486

View more
  24 in total

1.  Involvement of domain 3 in oligomerization by the protective antigen moiety of anthrax toxin.

Authors:  J Mogridge; M Mourez; R J Collier
Journal:  J Bacteriol       Date:  2001-03       Impact factor: 3.490

2.  A systematic study of site-specific GalNAc-type O-glycosylation modulating proprotein convertase processing.

Authors:  Katrine Ter-Borch Gram Schjoldager; Malene B Vester-Christensen; Christoffer K Goth; Thomas Nordahl Petersen; Søren Brunak; Eric P Bennett; Steven B Levery; Henrik Clausen
Journal:  J Biol Chem       Date:  2011-09-20       Impact factor: 5.157

3.  Identification of amino acid residues of anthrax protective antigen involved in binding with lethal factor.

Authors:  Vibha Chauhan; Rakesh Bhatnagar
Journal:  Infect Immun       Date:  2002-08       Impact factor: 3.441

4.  Protection against anthrax toxemia by hexa-D-arginine in vitro and in vivo.

Authors:  Miroslav S Sarac; Juan R Peinado; Stephen H Leppla; Iris Lindberg
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

5.  Identification of inhibitors using a cell-based assay for monitoring Golgi-resident protease activity.

Authors:  Julia M Coppola; Christin A Hamilton; Mahaveer S Bhojani; Martha J Larsen; Brian D Ross; Alnawaz Rehemtulla
Journal:  Anal Biochem       Date:  2007-01-17       Impact factor: 3.365

6.  Ser-Phosphorylation of PCSK9 (Proprotein Convertase Subtilisin-Kexin 9) by Fam20C (Family With Sequence Similarity 20, Member C) Kinase Enhances Its Ability to Degrade the LDLR (Low-Density Lipoprotein Receptor).

Authors:  Ali Ben Djoudi Ouadda; Marie-Soleil Gauthier; Delia Susan-Resiga; Emmanuelle Girard; Rachid Essalmani; Miles Black; Jadwiga Marcinkiewicz; Diane Forget; Josée Hamelin; Alexandra Evagelidis; Kevin Ly; Robert Day; Luc Galarneau; Francois Corbin; Benoit Coulombe; Artuela Çaku; Vincent S Tagliabracci; Nabil G Seidah
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-09-05       Impact factor: 8.311

7.  Synthetic small molecule furin inhibitors derived from 2,5-dideoxystreptamine.

Authors:  Guan-Sheng Jiao; Lynne Cregar; Jinzhi Wang; Sherri Z Millis; Cho Tang; Sean O'Malley; Alan T Johnson; Sina Sareth; Jason Larson; Gary Thomas
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-18       Impact factor: 11.205

8.  Disruption of anthrax toxin binding with the use of human antibodies and competitive inhibitors.

Authors:  N M Cirino; D Sblattero; D Allen; S R Peterson; J D Marks; P J Jackson; A Bradbury; B E Lehnert
Journal:  Infect Immun       Date:  1999-06       Impact factor: 3.441

9.  Endocytosis of the anthrax toxin is mediated by clathrin, actin and unconventional adaptors.

Authors:  Laurence Abrami; Mirko Bischofberger; Béatrice Kunz; Romain Groux; F Gisou van der Goot
Journal:  PLoS Pathog       Date:  2010-03-05       Impact factor: 6.823

10.  HIV-induced neuroinflammation: impact of PAR1 and PAR2 processing by Furin.

Authors:  Vatsal Sachan; Robert Lodge; Koichiro Mihara; Josée Hamelin; Christopher Power; Benjamin B Gelman; Morley D Hollenberg; Éric A Cohen; Nabil G Seidah
Journal:  Cell Death Differ       Date:  2019-01-25       Impact factor: 15.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.